The invention discloses a
piperlongumine-ligustrazine heterocomplex, a preparation method and a medical application. The
piperlongumine-ligustrazine heterocomplex is a compound, isomer or pharmaceutically acceptable salt as shown in the specific formula (I), wherein R1, R3 or R4 is independently selected from C1-3
alkyl groups or C1-3 alkoxygroups; R2 is selected from the
hydrogen (H) or
halogen. The compound has good water
solubility, is higher in proliferation inhibition activity for 4 colon
cancer cells than that of
piperlongumine. The compound, the isomer or the pharmaceutically acceptable salt can be applied to respects of medicines for treating or preventing tumors, or applies to respects of medicines relevant to metastatic
cancer, and can be applied to relevant diseases including but not limited to
brain gliomas, colon
cancer, metastatic colon cancer,
cell lung cancer, myoblastosis and the like.